Skip to content

Treatment Choices for Improving Adherence and Outcome

Patient Preference in Primary Care Depression Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00194948
Enrollment
60
Registered
2005-09-19
Start date
2003-09-30
Completion date
2007-05-31
Last updated
2013-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression

Brief summary

This study will determine the effectiveness of offering primary care patients their preferred treatment versus one that is less desirable in improving treatment adherence and outcome.

Detailed description

This study investigates whether offering primary care patients treatment that is congruent with their preferred first choice improves adherence and outcomes, in comparison to offering treatment that is not congruent with their preferred first choice. All subjects are offered a treatment with demonstrated efficacy, namely either the antidepressant medication escitalopram or Interpersonal Psychotherapy for 5 months. We hypothesize that patients who receive congruent treatment will be more likely to initiate treatment, adhere to treatment, and achieve depression remission.

Interventions

DRUGescitalopram
BEHAVIORALinterpersonal psychotherapy

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* age 21-99 * English-speaking * DSM-IV criteria for major depression

Exclusion criteria

* unable to give informed consent * MMSE\<24 * DSM-IV diagnosis of bipolar disorder, psychotic disorder, current alcohol or substance abuse * active suicide ideation * aphasia * acute or severe medical illness * currently receiving either antidepressant medication or psychotherapy

Design outcomes

Primary

MeasureTime frame
treatment initiation
treatment adherence

Secondary

MeasureTime frame
depressive symptomatology

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026